Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...

BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery technologies, has launched a 15-day dosing optimization study for its lead ...

Roche (OTCQX:RHHBY) shares closed ~4% higher in Europe on Monday as the maker of Ocrevus multiple sclerosis therapy announced two Phase 3 trial successes for fenebrutinib, its new experimental drug ...

A mum with multiple sclerosis has become the first patient in the UK to receive an experimental treatment that could slow or even stop progression of the disease. Emily Henders, 37, was given an ...

French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis drug and reported disappointing results from a late-stage study, sending ...

BARCELONA, Spain — Annual dosing of rituximab for relapsing-remitting multiple sclerosis (RRMS) was noninferior to the typical dosing schedule of once every 6 months, which could offer a more ...

A biology teacher and mother-of-two has become the first UK patient to receive a "gamechanger" therapy to treat multiple sclerosis (MS). Emily Henders, 37, from Bushey, Hertfordshire, was treated at ...

Rachelle Reagan was diagnosed four years ago with multiple sclerosis, which destroys myelin, a protective sheath that surrounds neurons. Air Force veteran gets it embellished with bright paint and ...